source
- Merck and Moderna’s personalized mRNA vaccine shows longer recurrence-free survival in phase 3 melanoma trialMerck and Moderna reported that their individualized mRNA cancer vaccine, given together with Keytruda, extended the time patients remained free of melanoma recurrence in a late-stage study. The p…
- Leo Pharma signs $435 million deal with Tanabe for rare skin disease drug dersimelagonLeo Pharma announced a licensing agreement with Mitsubishi Tanabe Pharma for worldwide rights to dersimelagon, an oral melanocortin-1 receptor agonist targeting rare genetic skin disorders. The dr…